News

Next Generation IgM Immunoassays

Spain - March 22, 2021

How Biokit is driving innovation in Immunoassays

Innovation is one of the strategic and fundamental Biokit pillars and we innovate at all levels, regarding biomaterials, assays, and manufacturing biotechnology processes. We aim to reinforce immunoassay know-how and technology capabilities, keeping in mind a final goal: increase efficiency and robustness, reduce time to market and streamline operations.

In Biokit, we enjoy, promote and benefit from a unique network of scientists, entrepreneurs and major players in the IVD sector allowing us to identify and incorporate the most innovative tools and technologies.

We work toward moving your immunoassay portfolio one-step beyond

Our innovation team worked towards the objective of developing a next-generation anti-toxoplasma IgM chemiluminescent immunoassay, with the following goals

  • To improve the performance and sensitivity of an existing commercial chemiluminescent immunoassay
  • To avoid animal use for antigen production
  • To increase robustness of calibrators & controls.

Our approach was to collaborate with academic institutions and innovative biotechnological companies to explore innovative solutions to address challenges and opportunities identified.

Next-gen igm immunoassays

By using an Anti-Toxoplasma IgM Chemiluminescent Immunoassay as a model, the approaches followed to reach the objectives were from one side innovate in the antigen used in the immunoassay and from the other side innovate in the sources for calibrators and controls. When looking to innovate in the antigen, specific IgM epitopes were identified through high throughput and multiplex technologies. Once the epitopes were identified, a multi-epitope synthetic peptide was synthetized and then coated in the magnetic particles of this next-generation IgM Chemiluminescent Immunoassay.

On the calibrators and controls side, the followed path was to use chimeric humanized IgM hybridomas as a source for calibrators and controls for this next generation IgM immunoassay.

Outcomes

The Next-generation Toxoplasma IgM Immunoassay was compared with a commercial Toxoplasma IgM and the obtained results were an increase of the sensitivity of 10% (up to 99%) and an increase of specificity of 4% (up to 97%).

In addition of reaching the objective of improving the sensitivity and specificity of an existing commercial Chemiluminescent Immunoassay, the objectives of avoiding animal requirement for antigen production and robust sources for calibrators & controls were also reached.

Find more details about this project in the Biokit Webinar Series: Next-Generation IgM Immunoassays.

Share Press Release:

LinkedIn twitter facebook

Contact us


Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

Data protection policy
DATA PROTECTION POLICY: In application of the Personal Data Protection Regulation, we inform that your personal data will be incorporated and processed in a file under the responsibility of BIOKIT SA for the purpose of maintaining the commercial relationship (order management and/or billing, sending product notices, managing business relationships, including conducting surveys, prospecting, statistical analysis and other activities related to the management of business visits), as well as to provide by any means (electronic or not), information about our products and / or services that may be of interest to you.
Data Controller:
Biokit SA
A083360183
Can Male s/n
08186 Lliça d´Amunt (Barcelona)
Spain

Data Processor: WERFENLIFE, S.A., with address at Plaza Europa, 21-23 - 08908 L'Hospitalet de Llobregat (Barcelona). CIF: A08754111M, and BIOKIT SA.
Data Protection Officer: DPO@werfen.com
Legal basis of the data processing: The processing is necessary for the execution of a commercial contract of product and/or service, as well as your consent with respect to commercial communications, supply of products and/or services, market research and improvement of our website.
Recipients or categories of recipients: Werfen companies and third parties to which WERFENLIFE, S.A. has entrusted the provision of services (hosting, training and communication services, organization of events), when legally or contractually required.
Storage Period: While you are a user of our products and/or services and/or of our website and whenever you have not opposed receiving commercial communications. Subsequently, the data will be maintained, duly blocked, for a period of 5 years.
Rights: You can exercise the rights of access, rectification or deletion, as well as request limitation of your data processing, oppose it, request the portability of your data, or revoke the consent given by writing to DPO-Biokit@werfen.com
Likewise, the data subject is entitled to lodge a complaint with the Spanish Data Protection Agency www.agpd.es – C/ Jorge Juan, 6 in Madrid
---------
The information you are sending us via this “Contact Us” form will be used for the sole purpose of responding to your request and, therefore, may be transferred to other Werfen companies or subsidiaries in other countries.
By clicking “I accept”, you agree that your data will be governed by our Data Protection Policy